Le Lézard

News by subject: Clinical Study

1 2 3 4 5 6 7

Today

07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...


27 march 2024

09:10
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request...


25 march 2024

08:10
In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing...

06:30
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008) AXS-12 statistically significantly reduced...


21 march 2024

07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced moving to the next...


19 march 2024

07:00
Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the first patient has been dosed in the PARADIGM Phase 3 trial of...

05:00
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of Company's achievements in 2023 and...


18 march 2024

07:30
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV-2 virusPhase II findings...

05:00
OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior...


15 march 2024

07:05
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from the University of Calgary's Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...


12 march 2024

09:00
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on...

07:15
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention...


11 march 2024

08:00
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , an artificial intelligence digital healthcare company, is pleased to announce that it has been accepted into the Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation...


7 march 2024

07:30
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney...


6 march 2024

07:35
Biogen Inc. announced interim 6-month biomarker data from the initial 29 participants in...

07:00
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual...


5 march 2024

16:30
Zymeworks Inc....

01:00
Brains Bioceutical Corp ("Brains Bio" or the "Company"), Brains Bio, a pioneer in the cannabinoid-based pharmaceutical industry, is proud to announce a significant breakthrough in the journey to a world's first solid Tetrahydrocannabinol (THC) as an...


29 february 2024

16:05
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025...


28 february 2024

07:30
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of...


27 february 2024

10:00
Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a...


21 february 2024

09:30
PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by...


20 february 2024

16:40
Calian Group Ltd. , a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions has won a contract to support a Phase 2 Clinical Trial of ZYUS Life Science's Trichomylin® softgel...


15 february 2024

07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six participants in Part 3 of...

07:00
Lifeist Wellness Inc. ("Lifeist" or the "Company") , a health-tech company that leverages advancements in science and technology to transform human wellness, is pleased to report, on behalf of its U.S. biosciences subsidiary Mikra Cellular Sciences...


14 february 2024

11:50
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis)....

08:30
FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: "More than 8,000 people in the U.S. are diagnosed with anal cancer each...


13 february 2024

07:00
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11 continues to demonstrate encouraging single-agent...


12 february 2024

08:50
HydroGraph Clean Power Inc. (the "Company" or "HydroGraph"), one of five certified graphene manufacturers in the world, today announced that positive test results from its research in combining its proprietary graphene with polyethylene...


8 february 2024

05:00
Genenta Science , a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully...


5 february 2024

07:30
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of...

04:00
Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine. A double-blinded placebo-controlled clinical trial sponsored by Blue...


1 february 2024

22:45
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the...

07:30
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral...


31 january 2024

07:30
Biogen Inc. today announced plans to reprioritize its resources in Alzheimer's disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will...


23 january 2024

12:35
Celiac patients in hospitals and long-term care residents who cannot advocate for themselves are often served food containing gluten, which can lead to horrendous symptoms and even death if they're fed unsafe food for long enough. Tiny amounts of...


17 january 2024

23:10
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the publication...


16 january 2024

10:00
January is Alzheimer's Awareness Month, recognised across Canada and internationally as an opportunity to reflect on the challenges faced by the growing number of people living with dementia, and their care partners. To underscore the urgency of this...


10 january 2024

07:00
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of...

07:00
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation...


9 january 2024

07:00
The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11 continues to demonstrate encouraging single-agent...


8 january 2024

07:30
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran...


3 january 2024

07:35
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac...


2 january 2024

08:00
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the...


21 december 2023

07:30
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that it received approval in Turkey from the Kocaeli University Clinical Research Ethics Committee to proceed with a Phase II trial for LSALT peptide, targeting the prevention and...


18 december 2023

07:30
Lantheus Holdings, Inc. (Lantheus) and POINT Biopharma Global Inc. (POINT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific...


15 december 2023

09:10
Biogen Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS® (omaveloxolone) for the...


14 december 2023

08:05
Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of...


13 december 2023

08:50
Ceapro Inc. ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the commencement of patient dosing in its...

07:25
Arch Biopartners Inc., ("Arch" or the "Company") , announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of...

1 2 3 4 5 6 7